Looking to expand your partner network with the latest in the field of RSV? Consider joining Inpart's global network for free.
News and Trends 23 Sep 2024
Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses
Discover Vicebio’s molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against RSV and hMPV.